Tianqing Ganping Diammonium Glycyrrhizinate Enteric-Coated Capsules For Hepatitis 50mg*24 Capsules*5 boxes

甘草酸二铵肠溶胶囊

Generic name: diammonium glycyrrhizinate enteric-coated capsules
Chinese Pinyin: Gancaosuan E’ran Changrong Jiaonang
Product name: Tianqing Ganping
Ingredients: The main ingredient of this product is diammonium glycyrrhizinate. The auxiliary materials are lecithin and starch.
Properties: This product is an enteric-coated hard capsule, the content is light yellow powder or granules.
Indications: This product is suitable for the treatment of acute and chronic hepatitis accompanied by elevated glutamyltransferase.
Specification: 50mg*24 capsules/box
Usage and dosage: Orally, 150mg once (3 capsules each time), 3 times a day.
Adverse reactions: Mainly include anorexia, nausea, vomiting, abdominal distension, skin itching, urticaria, dry mouth and edema, headache, dizziness, chest tightness, palpitations and increased blood pressure in the cardiovascular system. The above symptoms are generally mild. Stop the drug.
Contraindications: Those who are allergic to the main drug diammonium glycyrrhizinate are forbidden; those who are allergic to lecithin are forbidden; for patients with severe hypokalemia, hypernatremia, hypertension, heart failure, and renal failure.
Note: Blood pressure and serum potassium and sodium concentrations should be measured regularly during treatment. If hypertension, blood sodium retention, hypokalemia, etc. occur, the drug should be stopped or appropriately reduced.
Pharmacology and Toxicology: This product is the third-generation extract of the effective ingredients of the traditional Chinese medicine licorice. It has strong anti-inflammatory, protect liver cell membrane and improve liver function. The drug is similar in chemical structure to the steroid ring of aldosterone, which can hinder the inactivation of cortisone and aldosterone, thereby exerting a steroid-like effect, but without the adverse effects of corticosteroids.　
Pharmacokinetics: This product is absorbed from the intestine after oral administration, and its bioavailability is not affected by intestinal food. This product has enterohepatic circulation, and its internal processes are complex. The plasma concentration reaches the peak 8-12 hours after administration . The drug and its metabolites have strong binding power to proteins, and its binding rate is affected by the concentration of plasma proteins. Therefore, changes in blood drug concentration are closely related to enterohepatic circulation and protein binding. About 70% is excreted from feces through bile, 20% is excreted in the form of carbon dioxide from the respiratory tract, and approximately 2% is excreted in urine as it is.
Medication for pregnant women and lactating women: Not suitable for pregnant women.
Children's medication: The dosage and adverse reactions of neonates, infants and young children have not yet been determined, so it will not be used.
Medication for elderly patients: The experiment has not been conducted and there is no reliable reference.
Storage: Store in a sealed, dry place.
Packaging: Aluminum-plastic packaging. 12 tablets/plate, 2 plates/box.
Validity period: 24 months
Approval number: National Medicine Zhunzi H20040628
Company Name: Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd.